,42 Approximately 20% of MASLD cases progress to metabolic dysfunction-associated steatohepatitis, which is characterized by elevated systemic inflammatory markers such as high-sensitivity C-reactive protein and CXCL10.[43], [44], [45] Additionally, steatotic hepatocyte-derived extracellular vesicles have been shown to promote foam cell formation and accelerate atherosclerosis, further linking liver-derived inflammation with cardiovascular pathology.40 Here, CXCL10 is linked to metabolic dysfunction-associated steatotic liver disease.